ANNOUNCEMENT
Celebrating two years of BioStrateonLearn more Celebrating two years of BioStrateonLearn more Celebrating two years of BioStrateonLearn more

You lead the We shape the

Strategic advisory for life sciences and healthcare, where scientific depth meets commercial judgement

Decision-ready advice grounded in science

We bring a business mindset coupled with deep scientific rigor. Every recommendation is actionable and empirically grounded.

The strategy is the start, not the deliverable

Every strategic recommendation is made with execution in mind. We pressure-test it in the market, make introductions that move it forward, and refine the approach as conditions change.

Insights shaped by a trusted network

Our thinking draws on long-standing relationships with operators, executives, scientists and investors across life sciences and healthcare, which bring candid perspectives that rarely make it into published reports.

Scroll

Trusted thinking partners, not transactional consultants.

We advise on what serves your long-term position. If the evidence says walk away from a deal or a market, that is our recommendation, whatever it means for our fee.

“We’d rather lose a fee than a client.”

15+

Clients served across corporates, start-ups and investors

2

transactions closed in a short period of our journey

25+

years combined life sciences and healthcare strategy experience across the team

300+

Companies and investors in our network across the UK, US, India and Africa.

From strategy to transaction, one view of the science, the market and the deal.

We help you identify the right move and see it through to close. Engage us for a single stage or the full journey.

Strategy and intelligence

Capital and transactions

Strategy and intelligence

Growth strategy

Not just compiling data, but defining where you have the right to win, and why. Positioning, roadmap and go-to-market rooted in customer economics.

  • ◆Market entry and segment prioritisation
  • ◆Competitive positioning and value proposition
  • ◆Pricing, access and GTM plan
Explore growth strategy
Right to winCommercial pull →Scientific edge →

Strategy and intelligence

Custom intelligence

Not paid interviews, but operator- and investor-level insight into the true state of the industry, mapped directly to the decision in front of you.

  • ◆Primary research with senior decision-makers
  • ◆Technology and therapy landscape maps
  • ◆Market sizing and pricing benchmarks
Explore custom intelligence
OperatorsInvestorsPharma BDCliniciansPayersPartnersYourquestion

Strategy and intelligence

Due diligence

Technical and commercial diligence on assets, platforms and companies, so the science is tested before the capital is committed.

  • ◆Scientific and technology assessment
  • ◆Market, competition and commercial case
  • ◆Risks, synergies and valuation inputs
Explore due diligence
DealMarketDataScience

Capital and transactions

M&A advisory

Buy-side and sell-side support that gets you across the line: from the expansion thesis and the target universe to valuation, structuring and diligence.

  • ◆Acquisition thesis and adjacency map
  • ◆Scored target universe and shortlist
  • ◆Outreach, valuation and deal support
Explore M&A advisory
Universe mapped700+Shortlisted on fit~100Acquired2

Capital and transactions

Licensing and partnering

Build, buy or partner: we develop and test the partnership thesis that accelerates your roadmap, then help structure deals that work for both sides.

  • ◆Build vs buy vs partner thesis
  • ◆In- and out-licensing, asset scouting
  • ◆Partner mapping across pharma, tech and diagnostics
Explore licensing and partnering
YourroadmapBuildBuyPartner

Capital and transactions

Fundraising

How much to raise, when, and from whom, to protect dilution and reach the next milestone. Then the story, the model and the investor process.

  • ◆Round sizing, valuation and capital stack
  • ◆Equity story and investor deck
  • ◆Investor mapping, introductions and term sheets
Explore Startup Advisory
Milestone reachedSeedBridgeSeries A

Startup advisory

Embedded strategic partners to founders

We operate as an extension of the founding team, aligning science, business and execution. Bring us in across all five pillars, or on the one that matters most right now.

We understand the urgency, the uncertainty and the scrappiness required to succeed
Translating science into a compelling narrative
Fundraising strategy and execution
Go-to-market strategy
Partnering and collaborations
Organisational and operating model

Insights

Industry thought leadership

Case studies and market outlooks, along with The BioStrat Brief, our newsletter offering a dealmaker’s view on fundraising, M&A, strategy and markets.

FAQ

Frequently asked questions

We are a strategic advisory firm that works in life sciences and healthcare. We run two practices. For established companies we work on market intelligence, growth strategy, new markets and partnering, which usually leads into transactions: M&A, fundraising and licensing. For a small number of start-ups we act as long-term advisors on go-to-market, partnering and fundraising. Most of our engagements end with transactions: fundraise, a licensing deal or an M&A process.

None of the three exactly. We are strategic advisors who also run transactions. We do not chase whichever space is fashionable or force a deal: we start from where the science and the business can genuinely win, then run the process to get there. We do not manage a fund of our own. We bring in investors, partners and acquirers from our network and manage the process with you.

Biopharma, Pharma services, diagnostics and genomics, digital health, TechBio, CROs and healthcare services. We do bring an unparalleled depth in tech X life sciences space. We work with founders from pre-seed onwards, with scaled and profitable companies on a range of projects including sell side advisory, and with corporates and private equity on the buy side.

Usually a modest retainer plus a success fee. The retainer covers the preparation work that decides the outcome; the success fee is paid only when a transaction closes, and as a percentage it falls as the deal size rises. Most of what we earn, we earn when you do. Start-up engagements can be structured differently.

Yes, on an anonymized basis. Examples include a seed round for a pharma commercial analytics AI platform, sale processes for data and bioinformatics services businesses, a buy-side platform search for a global CRO, and a technology-enabled M&A landscape for a commercialisation services group. We name clients only with their permission. Reach out to see if we have more examples from your exact space.

Let’s shape what’s next.

A business to grow, a capital raise or M&A discussion on cards, let's talk

ANNOUNCEMENT
Celebrating two years of BioStrateonLearn more Celebrating two years of BioStrateonLearn more Celebrating two years of BioStrateonLearn more

You lead the We shape the

Strategic advisory for life sciences and healthcare, where scientific depth meets commercial judgement

Decision-ready advice grounded in science

We bring a business mindset coupled with deep scientific rigor. Every recommendation is actionable and empirically grounded.

The strategy is the start, not the deliverable

Every strategic recommendation is made with execution in mind. We pressure-test it in the market, make introductions that move it forward, and refine the approach as conditions change.

Insights shaped by a trusted network

Our thinking draws on long-standing relationships with operators, executives, scientists and investors across life sciences and healthcare, which bring candid perspectives that rarely make it into published reports.

Scroll

Trusted thinking partners, not transactional consultants.

This piece is a core pillar of our work.

We advise on what serves your long-term position. If the evidence says walk away from a deal or a market, that is our recommendation, whatever it means for our fee.

“We’d rather lose a fee than a client.”

15+

Clients served across corporates, start-ups and investors

2

transactions closed in a short period of our journey

25+

years combined life sciences and healthcare strategy experience across the team

300+

Companies and investors in our network across the UK, US, India and Africa.

From strategy to transaction, one view of the science, the market and the deal.

We help you identify the right move and see it through to close. Engage us for a single stage or the full journey.

Strategy and intelligence

Not just compiling data, but defining where you have the right to win, and why. Positioning, roadmap and go-to-market rooted in customer economics.

  • ◆Market entry and segment prioritisation
  • ◆Competitive positioning and value proposition
  • ◆Pricing, access and GTM plan
Right to winCommercial pull →Scientific edge →
Explore growth strategy →

Not paid interviews, but operator- and investor-level insight into the true state of the industry, mapped directly to the decision in front of you.

  • ◆Primary research with senior decision-makers
  • ◆Technology and therapy landscape maps
  • ◆Market sizing and pricing benchmarks
OperatorsInvestorsPharma BDCliniciansPayersPartnersYourquestion
Explore custom intelligence →

Technical and commercial diligence on assets, platforms and companies, so the science is tested before the capital is committed.

  • ◆Scientific and technology assessment
  • ◆Market, competition and commercial case
  • ◆Risks, synergies and valuation inputs
DealMarketDataScience
Explore due diligence →

Capital and transactions

Buy-side and sell-side support that gets you across the line: from the expansion thesis and the target universe to valuation, structuring and diligence.

  • ◆Acquisition thesis and adjacency map
  • ◆Scored target universe and shortlist
  • ◆Outreach, valuation and deal support
Universe mapped700+Shortlisted on fit~100Acquired2
Explore M&A advisory →

Build, buy or partner: we develop and test the partnership thesis that accelerates your roadmap, then help structure deals that work for both sides.

  • ◆Build vs buy vs partner thesis
  • ◆In- and out-licensing, asset scouting
  • ◆Partner mapping across pharma, tech and diagnostics
YourroadmapBuildBuyPartner
Explore licensing and partnering →

How much to raise, when, and from whom, to protect dilution and reach the next milestone. Then the story, the model and the investor process.

  • ◆Round sizing, valuation and capital stack
  • ◆Equity story and investor deck
  • ◆Investor mapping, introductions and term sheets
Milestone reachedSeedBridgeSeries A
Explore Startup Advisory →

Startup advisory

Embedded strategic partners to founders

We operate as an extension of the founding team, aligning science, business and execution.

Talk to us about your needs Explore Startup Advisory

Insights

Industry thought leadership

Case studies and market outlooks, along with The BioStrat Brief, our newsletter offering a dealmaker’s view on fundraising, M&A, strategy and markets.

FAQ

Frequently asked questions

We are a strategic advisory firm that works in life sciences and healthcare. We run two practices. For established companies we work on market intelligence, growth strategy, new markets and partnering, which usually leads into transactions: M&A, fundraising and licensing. For a small number of start-ups we act as long-term advisors on go-to-market, partnering and fundraising. Most of our engagements end with transactions: fundraise, a licensing deal or an M&A process.

None of the three exactly. We are strategic advisors who also run transactions. We do not chase whichever space is fashionable or force a deal: we start from where the science and the business can genuinely win, then run the process to get there. We do not manage a fund of our own. We bring in investors, partners and acquirers from our network and manage the process with you.

Biopharma, Pharma services, diagnostics and genomics, digital health, TechBio, CROs and healthcare services. We do bring an unparalleled depth in tech X life sciences space. We work with founders from pre-seed onwards, with scaled and profitable companies on a range of projects including sell side advisory, and with corporates and private equity on the buy side.

Usually a modest retainer plus a success fee. The retainer covers the preparation work that decides the outcome; the success fee is paid only when a transaction closes, and as a percentage it falls as the deal size rises. Most of what we earn, we earn when you do. Start-up engagements can be structured differently.

Yes, on an anonymized basis. Examples include a seed round for a pharma commercial analytics AI platform, sale processes for data and bioinformatics services businesses, a buy-side platform search for a global CRO, and a technology-enabled M&A landscape for a commercialisation services group. We name clients only with their permission. Reach out to see if we have more examples from your exact space.

Let’s shape what’s next.

A business to grow, a capital raise or M&A discussion on cards, let's talk

Contact Us
ANNOUNCEMENT
Celebrating two years of BioStrateonLearn more Celebrating two years of BioStrateonLearn more Celebrating two years of BioStrateonLearn more

You lead the We shape the

Strategic advisory for life sciences and healthcare, where scientific depth meets commercial judgement

Decision-ready advice grounded in science

We bring a business mindset coupled with deep scientific rigor. Every recommendation is actionable and empirically grounded.

The strategy is the start, not the deliverable

Every strategic recommendation is made with execution in mind. We pressure-test it in the market, make introductions that move it forward, and refine the approach as conditions change.

Insights shaped by a trusted network

Our thinking draws on long-standing relationships with operators, executives, scientists and investors across life sciences and healthcare, which bring candid perspectives that rarely make it into published reports.

Scroll

Trusted thinking partners, not transactional consultants.

This piece is a core pillar of our work.

We advise on what serves your long-term position. If the evidence says walk away from a deal or a market, that is our recommendation, whatever it means for our fee.

“We’d rather lose a fee than a client.”

15+

Clients served across corporates, start-ups and investors

2

transactions closed in a short period of our journey

25+

years combined life sciences and healthcare strategy experience across the team

300+

Companies and investors in our network across the UK, US, India and Africa.

From strategy to transaction, one view of the science, the market and the deal.

We help you identify the right move and see it through to close. Engage us for a single stage or the full journey.

Strategy and intelligence

Not just compiling data, but defining where you have the right to win, and why. Positioning, roadmap and go-to-market rooted in customer economics.

  • ◆Market entry and segment prioritisation
  • ◆Competitive positioning and value proposition
  • ◆Pricing, access and GTM plan
Right to winCommercial pull →Scientific edge →
Explore growth strategy →

Not paid interviews, but operator- and investor-level insight into the true state of the industry, mapped directly to the decision in front of you.

  • ◆Primary research with senior decision-makers
  • ◆Technology and therapy landscape maps
  • ◆Market sizing and pricing benchmarks
OperatorsInvestorsPharma BDCliniciansPayersPartnersYourquestion
Explore custom intelligence →

Technical and commercial diligence on assets, platforms and companies, so the science is tested before the capital is committed.

  • ◆Scientific and technology assessment
  • ◆Market, competition and commercial case
  • ◆Risks, synergies and valuation inputs
DealMarketDataScience
Explore due diligence →

Capital and transactions

Buy-side and sell-side support that gets you across the line: from the expansion thesis and the target universe to valuation, structuring and diligence.

  • ◆Acquisition thesis and adjacency map
  • ◆Scored target universe and shortlist
  • ◆Outreach, valuation and deal support
Universe mapped700+Shortlisted on fit~100Acquired2
Explore M&A advisory →

Build, buy or partner: we develop and test the partnership thesis that accelerates your roadmap, then help structure deals that work for both sides.

  • ◆Build vs buy vs partner thesis
  • ◆In- and out-licensing, asset scouting
  • ◆Partner mapping across pharma, tech and diagnostics
YourroadmapBuildBuyPartner
Explore licensing and partnering →

How much to raise, when, and from whom, to protect dilution and reach the next milestone. Then the story, the model and the investor process.

  • ◆Round sizing, valuation and capital stack
  • ◆Equity story and investor deck
  • ◆Investor mapping, introductions and term sheets
Milestone reachedSeedBridgeSeries A
Explore Startup Advisory →

Startup advisory

Embedded strategic partners to founders

We operate as an extension of the founding team, aligning science, business and execution.

Talk to us about your needs Explore Startup Advisory

Insights

Industry thought leadership

Case studies and market outlooks, along with The BioStrat Brief, our newsletter offering a dealmaker’s view on fundraising, M&A, strategy and markets.

FAQ

Frequently asked questions

We are a strategic advisory firm that works in life sciences and healthcare. We run two practices. For established companies we work on market intelligence, growth strategy, new markets and partnering, which usually leads into transactions: M&A, fundraising and licensing. For a small number of start-ups we act as long-term advisors on go-to-market, partnering and fundraising. Most of our engagements end with transactions: fundraise, a licensing deal or an M&A process.

None of the three exactly. We are strategic advisors who also run transactions. We do not chase whichever space is fashionable or force a deal: we start from where the science and the business can genuinely win, then run the process to get there. We do not manage a fund of our own. We bring in investors, partners and acquirers from our network and manage the process with you.

Biopharma, Pharma services, diagnostics and genomics, digital health, TechBio, CROs and healthcare services. We do bring an unparalleled depth in tech X life sciences space. We work with founders from pre-seed onwards, with scaled and profitable companies on a range of projects including sell side advisory, and with corporates and private equity on the buy side.

Usually a modest retainer plus a success fee. The retainer covers the preparation work that decides the outcome; the success fee is paid only when a transaction closes, and as a percentage it falls as the deal size rises. Most of what we earn, we earn when you do. Start-up engagements can be structured differently.

Yes, on an anonymized basis. Examples include a seed round for a pharma commercial analytics AI platform, sale processes for data and bioinformatics services businesses, a buy-side platform search for a global CRO, and a technology-enabled M&A landscape for a commercialisation services group. We name clients only with their permission. Reach out to see if we have more examples from your exact space.

Let’s shape what’s next.

A business to grow, a capital raise or M&A discussion on cards, let's talk

Contact Us